Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Down – What’s Next?

Posted by Francis Steltz on May 28th, 2026

Shares of Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY – Get Free Report) gapped down before the market opened on Thursday . The stock had previously closed at $16.81, but opened at $16.05. Daiichi Sankyo shares last traded at $16.62, with a volume of 255,082 shares changing hands.

Analyst Ratings Changes

Separately, Zacks Research raised shares of Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a report on Tuesday, May 5th. One analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, Daiichi Sankyo has an average rating of “Buy”.

View Our Latest Report on DSNKY

Daiichi Sankyo Stock Up 0.7%

The company has a quick ratio of 1.85, a current ratio of 2.69 and a debt-to-equity ratio of 0.18. The company has a market cap of $32.07 billion, a PE ratio of 18.01, a P/E/G ratio of 1.21 and a beta of -0.25. The stock has a 50-day moving average of $17.47 and a 200-day moving average of $19.64.

Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) last issued its quarterly earnings data on Monday, May 11th. The company reported $0.15 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.18). Daiichi Sankyo had a return on equity of 15.74% and a net margin of 12.32%.The business had revenue of $3.76 billion during the quarter, compared to analysts’ expectations of $3.74 billion. Daiichi Sankyo has set its FY 2026 guidance at 0.910-0.910 EPS. Sell-side analysts predict that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.91 earnings per share for the current fiscal year.

Daiichi Sankyo Company Profile

(Get Free Report)

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.